Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05714839 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
A Phase 1 study of Multiple Myeloma, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 153
- Enrollment target
- 20
- Study locations
NCT05714839: Recruiting Phase 1 study of Multiple Myeloma, sponsored by GlaxoSmithKline.
NCT05714839 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 153 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (72% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05714839, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 153 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study consists of three parts: * Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). * Part 2 The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different dose ratios of belantamab mafodotin in combination with Unconjugated belantamab antibody (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). * Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the unconjugated belantamab antibody, either alone or in combination with belantamab mafodotin alongside the standard of care (SoC) pomalidomide-dexamethasone backbone. The study will focus on patients with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.
Conditions Studied
Interventions
- DRUG Unconjugated belantamab antibody
- DRUG Belantamab mafodotin
- DRUG Unconjugated belantamab antibody and belantamab mafodotin
- DRUG Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone, with or without belantamab mafodotin
Study Locations (20)
Other
- GSK Investigational Site - Ciudadela
- GSK Investigational Site - San Juan Bautista
- GSK Investigational Site - Viedma
- GSK Investigational Site - Joinville
- GSK Investigational Site - Salvador
- GSK Investigational Site - São Paulo
- GSK Investigational Site - Aomori
- GSK Investigational Site - Chiba
- GSK Investigational Site - Osaka
- GSK Investigational Site - Tokyo
- GSK Investigational Site - Gdansk
- GSK Investigational Site - Lublin
- GSK Investigational Site - Seoul
- GSK Investigational Site - Seoul
Tennessee
- GSK Investigational Site - Chattanooga
- GSK Investigational Site - Nashville
Michigan
- GSK Investigational Site - Grand Rapids
North Carolina
- GSK Investigational Site - Chapel Hill
Victoria
- GSK Investigational Site - Fitzroy
Western Australia
- GSK Investigational Site - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2023-06-14 |
| Est. Completion | 2029-12-03 |
| Phase | Phase 1 |
What NCT05714839 shows while recruiting
NCT05714839 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Unconjugated belantamab antibody is the first listed.
NCT05714839 names 20 study sites across 6 states, led by Other, Tennessee, Michigan.
Frequently Asked Questions
What is clinical trial NCT05714839 about?
NCT05714839 is a clinical study titled "A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments". The study consists of three parts: * Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab antibody in participants with refractory multiple myeloma (RRMM) who have received at least 3 pri...
What is the current status of trial NCT05714839?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 153 participants. The study started on 2023-06-14. Estimated completion is 2029-12-03.
What conditions does trial NCT05714839 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05714839?
The interventions under investigation include: Unconjugated belantamab antibody (DRUG), Belantamab mafodotin (DRUG), Unconjugated belantamab antibody and belantamab mafodotin (DRUG), Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone, with or without belantamab mafodotin (DRUG).
Who is sponsoring clinical trial NCT05714839?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05714839 being conducted?
This trial has 20 study locations across Michigan, North Carolina, Tennessee, Victoria, Western Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05714839's enrollment target sits among peer trials
153 133rd of 438 higher than 306 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT06293352 · 153 participants · NA
Real-component Vs All-cement Articulating Spacers for Periprosthetic Knee Infection
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI